Acticor Biotech announces the granting of a patent in Europe relating to glenzocimab, its innovative product for the treatment of cardiovascular emergencies

  • This patent protects the use of glenzocimab in thrombotic diseases until 2036
  • This patent has already been granted in the United States and Singapore and is in the process of being granted in other countries such as Japan

PARIS–(BUSINESS WIRE)–Regulatory News:

ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of cardiovascular emergencies, in particular stroke, announces that the European Patent Office (EPO ) issued a new patent that strengthens Actor Biotech’s patent portfolio. It ensures the protection of glenzocimab in thrombotic diseases in Europe until 2036.

This grant in Europe completes those already obtained in November 2020 in the United States and in November 2021 in Singapore, also protecting glenzocimab until 2036. The patent is also being examined in other countries such as Japan.

To date, three patent families, comprising 4 issued patents and 33 pending patent applications, protect glenzocimab and its use.

Sophie Binay, Deputy CEO and Scientific Director, comments “The issuance of this patent and Europeprotecting the use of glenzocimab in thrombotic diseases, represents an important step for the development of our drug candidate and its future commercialization, and strengthens Actor’s patent portfolio. He has been expanded to other major territories with issuance in the United States and intent for issuance in Japan ensuring protection until 2036. In addition, thanks to its historic commitments with INSERM, Acticor Biotech holds the exclusive enjoyment of commercial exploitation rights of this patent”


Acticor Biotech is a clinical-stage biotechnology company, a spin-off of INSERM, which aims to develop an innovative drug for the treatment of cardiovascular emergencies, in particular ischemic strokes.

Acticor Biotech is developing glenzocimab (ACT017), a humanized monoclonal antibody fragment (Fab) directed against a new target of major interest, platelet glycoprotein VI (GPVI). Glenzocimab inhibits the attachment of platelets to the thrombus without affecting physiological haemostasis, which limits the risk of haemorrhage, in particular intracerebral haemorrhage.

In May 2022, Acticor Biotech presented at ESOC, the positive results of its phase 1b/2a study, ACTIMIS, confirming the safety profile and showing a reduction in mortality and intracerebral haemorrhages in the group treated with glenzocimab in patients with stroke. The efficacy of glenzocimab is currently being evaluated in an international phase 2/3 study, ACTISAVE, which will include 1,000 patients.

Acticor Biotech is supported by a panel of European and international investors (Karista, Go Capital, Newton Biocapital, CMS Medical Venture Investment (HK) Limited, A&B (HK) Limited, Mirae Asset Capital, Anaxago, Primer Capital, Mediolanum farmaceutici and the Armesa Foundation) and has been listed on Euronext Growth Paris since November 2021 (ISIN: FR0014005OJ5 – ALACT).

For more information, visit:



Managing Director and Founder

[email protected]
T. : +33 (0)6 76 23 38 13

Sophie BINAY, PhD

Deputy CEO and Scientific Director

[email protected]
T. : +33 (0)6 76 23 38 13

Mathilde BOHIN / Olivier BRICAUD

Investor Relations

[email protected]
T. : +33 (0)1 44 71 94 95